Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLC001
MIFTS: 44

Placenta Accreta

Categories: Fetal diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Placenta Accreta

About this section

MalaCards integrated aliases for Placenta Accreta:

Name: Placenta Accreta 11 43 14 16 71

Classifications:

MalaCards categories:
Global: Fetal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:4744
MeSH 43 D010921
NCIt 49 C26856
SNOMED-CT 68 70129008
UMLS 71 C0032044
Sources

Summaries for Placenta Accreta

About this section

Disease Ontology: 11 A placenta disease that is characterized by an abnormally deep attachment of the placenta, through the endometrium and into the myometrium.

MalaCards based summary: Placenta Accreta is related to placenta praevia and preterm premature rupture of the membranes. An important gene associated with Placenta Accreta is OXT (Oxytocin/Neurophysin I Prepropeptide), and among its related pathways/superpathways are Signal Transduction and PAK Pathway. The drugs Vasodilator Agents and Methylene blue have been mentioned in the context of this disorder. Affiliated tissues include placenta, uterus and myeloid, and related phenotypes are homeostasis/metabolism and cardiovascular system
Sources

Related Diseases for Placenta Accreta

About this section

Diseases related to Placenta Accreta via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 placenta praevia 32.6 PGF PAPPA OXT
2 preterm premature rupture of the membranes 30.8 PGF PAPPA OXT
3 ectopic pregnancy 30.7 PAPPA OXT CGB3 AFP
4 chorioamnionitis 30.5 VEGFA OXT FLT1
5 arteriovenous malformation 30.5 VEGFA TEK KDR ANGPT2
6 eclampsia 30.5 VEGFA PGF PAPPA OXT FLT1
7 limb ischemia 30.4 VEGFA TEK KDR
8 gestational trophoblastic neoplasm 30.4 PGF PAPPA OXT MIR518B CGB3 AFP
9 placental abruption 30.2 PGF PAPPA OXT FLT1 CGB3 AFP
10 down syndrome 30.2 VEGFA PGF PAPPA CGB3 AFP
11 severe pre-eclampsia 30.0 VEGFA SERPINE1 PGF PAPPA OXT FLT1
12 macular degeneration, age-related, 1 29.7 VEGFA TEK PGF KDR FLT1 ANGPT2
13 pre-eclampsia 29.7 VEGFA SERPINE1 PGF PAPPA OXT KDR
14 endometriosis 29.6 VEGFA RXFP1 KDR FLT1
15 pulmonary hypertension 29.5 VEGFA TEK SERPINE1 PGF KDR FLT1
16 endometrial cancer 29.2 VEGFA SERPINE1 KDR FLT1 CTNNB1 CDH1
17 placental insufficiency 29.1 VEGFA TEK SERPINE1 PGF PAPPA KDR
18 diabetes mellitus 28.0 VEGFA TEK SERPINE1 PGF PAPPA OXT
19 disseminated intravascular coagulation 10.6
20 asherman's syndrome 10.5
21 endometritis 10.5
22 oculodentodigital dysplasia 10.4
23 neuraminidase deficiency 10.4
24 leiomyoma, uterine 10.3
25 thrombophilia due to thrombin defect 10.3
26 leiomyoma 10.3
27 amenorrhea 10.3
28 pulmonary embolism 10.3
29 uterine inversion 10.3
30 intermediate malignant teratoma 10.3 PAPPA AFP
31 acquired hemangioma 10.3 VEGFA OXT
32 subserous uterine fibroid 10.3 OXT AFP
33 adult respiratory distress syndrome 10.3
34 toxic shock syndrome 10.3
35 autoimmune polyglandular syndrome type 3 10.3
36 goblet cell carcinoid 10.3 CTNNB1 CDH1
37 twin-to-twin transfusion syndrome 10.3 PGF PAPPA FLT1
38 familiar ovarian carcinoma 10.3 TEK PGF ANGPT2
39 neonatal anemia 10.3 PGF PAPPA FLT1
40 rubeosis iridis 10.3 VEGFA PGF
41 pyogenic granuloma 10.3 VEGFA TEK ANGPT2
42 vaginal adenoma 10.3 PGF OXT CTNNB1
43 vaginal benign neoplasm 10.3 PGF OXT CTNNB1
44 renal pelvis adenocarcinoma 10.3 CDH1 AFP
45 hypertensive encephalopathy 10.2 VEGFA PGF FLT1
46 persistent fetal circulation syndrome 10.2 VEGFA PGF OXT
47 chorioangioma 10.2 PAPPA AFP
48 endophthalmitis 10.2 VEGFA PGF FLT1
49 chromosomal triplication 10.2 PAPPA CGB3 AFP
50 uterine anomalies 10.2

Graphical network of the top 20 diseases related to Placenta Accreta:



Diseases related to Placenta Accreta
Sources

Symptoms & Phenotypes for Placenta Accreta

About this section

MGI Mouse Phenotypes related to Placenta Accreta:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 AFP ANGPT2 BDKRB2 CDH1 CGB3 CTNNB1
2 cardiovascular system MP:0005385 10.07 ANGPT2 BDKRB2 CDH1 CTNNB1 DOCK4 FLT1
3 normal MP:0002873 10.06 BDKRB2 CDH1 CTNNB1 FLT1 KDR MIR34A
4 endocrine/exocrine gland MP:0005379 10.06 AFP ANGPT2 BDKRB2 CDH1 CGB3 CTNNB1
5 neoplasm MP:0002006 10.03 AFP CDH1 CTNNB1 DOCK4 MIR34A PGF
6 respiratory system MP:0005388 9.76 ANGPT2 CTNNB1 KDR MIR34A PGF RXFP1
7 reproductive system MP:0005389 9.73 AFP ANGPT2 BDKRB2 CDH1 CGB3 CTNNB1
8 integument MP:0010771 9.44 ANGPT2 BDKRB2 CDH1 CTNNB1 KDR MIR29A
Sources

Drugs & Therapeutics for Placenta Accreta

About this section

Drugs for Placenta Accreta (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 12)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vasodilator Agents Phase 4
2
Methylene blue Approved, Investigational 61-73-4 6099
3
Nicotine Approved 54-11-5 942 89594
4
Carbetocin Approved, Investigational 37025-55-1 16681432
5
Oxytocin Approved, Vet_approved 50-56-6 439302 53477758
6
Morphine Approved, Investigational 57-27-2 5288826
7 Kava Approved, Investigational, Nutraceutical 9000-38-8
8
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
9 Arginine Vasopressin
10 Vasopressins
11 Liver Extracts
12 Anti-Inflammatory Agents

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study (TAPPAS): A Randomized, Placebo-controlled Double Blind Trial Completed NCT02806024 Phase 4 Tranexamic Acid;Placebo Drug
2 The Role of Transdermal Carbon Dioxide in Malondialdehyde Level as Predictor of Ischemia Reperfusion Injury in Patients Underwent Abdominal Aortic Temporary Cross Clamp Recruiting NCT05205304 Phase 4 D'Oxyva
3 Management of Placenta Accreta Spectrum Unknown status NCT04609527 Phase 2, Phase 3
4 Tranexamic Acid in Adherent Placenta (TAP), a Randomized Clinical Trial Withdrawn NCT02329756 Phase 3 Tranexamic Acid (TXA);Sodium Chloride 0.9%
5 Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion: A Prospective, Single-center, Open, and Single-arm Clinical Trial Recruiting NCT04927988 Phase 1
6 MRI for the Diagnosis of Placenta Accreta Spectrum Unknown status NCT04151979
7 The Efficacy of Ultrasound in Predicting Operative Findings and Co-morbidities in Cesarean Section Among Cases of Placenta Accreta Unknown status NCT03286998
8 Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum Unknown status NCT04628169
9 Accuracy of Three /Four-dimensional Ultrasound in Diagnosing Placenta Accreta Spectrum: A Prospective Study Unknown status NCT04229953
10 Bladder Filling in Cesarean Hysterectomy for Placenta Percreta: A Randomized Trial Unknown status NCT04210479
11 Alpha-fetoprotein as a Biochemical Marker in Prediction of Placenta Acreta Increta Percreta Unknown status NCT04082507
12 Gray-scale , Colour Doppler Ultrasound and Magnetic Resonance Imaging for Diagnosis of Placenta Accreta Unknown status NCT03813212
13 Comparative Study Between Intraoperative Ureteric Dissection and Preoperative Ureteric Stenting in Women With Abnormally Invasive Placenta Unknown status NCT03763916
14 Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta in a High Risk Population Unknown status NCT02784886
15 Incidence of Placenta Accreta & it's Complications in Cases of Previous Cesarean With Placenta Previa Anterior Unknown status NCT02606474
16 Placenta Accreta Spectrum International Database (PAS-ID): Project Protocol Unknown status NCT04384510
17 Preplacental Delivery Intervention for Uterine Conservation Protocol: a Novel Approach for Management of Placenta Accreta Unknown status NCT03273569
18 is There Any Superior Benefit of Multidisciplinary Team in Management of Placenta Accreta Unknown status NCT03372538
19 Predictive Value of Cell-free Fetal DNA Concentration in the Maternal Plasma for Abnormal Placental Invasion in Cases of Placenta Previa. Unknown status NCT03638024
20 Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler in Cases of Placenta Accreta Unknown status NCT03530475
21 Bilateral Internal Iliac Artery Ligation Before Cesarean Hysterectomy : A Randomized Controlled Trial Unknown status NCT03129035
22 Antenatal Diagnosis of Placental Attachment Disorders Unknown status NCT02442518
23 Detection of Placenta Accreta by Means of Volatile Organic Compounds in Exhaled Women Breath. A Prospective Case Control Study. Unknown status NCT03947047
24 Comparison Between the Role of Transabdominal Ultrasound Versus Transvaginal Ultrasound in Evaluation of Placental Invasion in Cases of Placenta Previa Anterior Wall With Previous Uterine Scar Unknown status NCT03437291
25 MOGGE PAR-A and PAR-P Scores for Prediction of Adverse Outcomes of Placenta Accreta Spectrum: A Multi-center International Validation Study Protocol Unknown status NCT04525001
26 Comparison of N&H Sandwich Technique and Cesarean Hysterectomy in Management of Placenta Accreta Spectrum: A Randomized Controlled Trial Unknown status NCT03701386
27 Accuracy of Placenta Accreta Index in Diagnosing Placenta Accreta Spectrum: A Prospective Study Completed NCT04314791
28 Risk Factors for Occurrence of Placenta Accrete Spectrum Following Primary Cesarean Delivery Completed NCT04264169
29 Rotational Thromboelastometry During Cesarean Section as a Predictive Evaluation for Progression of Intraoperative Massive Hemorrhage in Parturients With a Potential Risk of Perioperative Hemorrhage: a Prospective Observational Study Completed NCT04213755
30 Early Prediction of Placenta Accreta by 2 Dimensional Transvaginal Ultrasound and Color Doppler Completed NCT03032770
31 Conservative Surgery for Abnormally Invasive Placenta: A New Technique Completed NCT04193618
32 Tourniquet on the Low Segment of the Uterus Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta: Old But Gold Completed NCT03707132
33 The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta Completed NCT04683562
34 TUI 3D in Diagnosis of Placenta Accreta: Comparison With Gray-scale and Color Doppler Techniques Completed NCT02712099
35 Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population Completed NCT02302573 contast-enhanced ultrasound with sonovue
36 Obstetric Hysterectomy Versus Conservative Surgery for Management of Patients With Morbidly Adherent Placenta as Regard Maternal Morbidity and Mortality Completed NCT03327818
37 Clinical Situations at High Risk of Placenta Accreta / Percreta: Impact of Diagnostic Methods and Management on Maternal Morbidity. Completed NCT02010229
38 Does Serum BNP Predict Abnormal Placental Invasion During Pregnancy Completed NCT04215484
39 Conservative Surgical Novel Technique of Placenta Accreta in Menoufia University Hospital Completed NCT04161521
40 Cervico-Isthmic Compression Suture Versus Anterior Wall Uterine Resection in Cases of Morbidly Adherent Anterior Situated Placenta Completed NCT04579172
41 A.Chohan Continuous Squeezing Suture (ACCSS) for Controlling Hemorrhage From the Lower Uterine Segment at the Cesarean Section for Placenta Previa / Accreta: a Case Series Completed NCT04660578
42 Validity of Internal Iliac Artery Ligation With Cervico Isthmic Compression Suture During Conservative Management of Placenta Accreta Spectrum Completed NCT04593303
43 The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta Completed NCT04573452
44 the Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta Completed NCT02966197
45 Surgical Management of Placenta Accreta a Three Year Experience at King Hussein Medical Center Completed NCT03668795
46 Correlation Between Pulmonary Artery Doppler And Other Ultrasonographic Markers With Neonatal Outcome In Placenta Accreta Spectrum Patients Completed NCT04911322
47 Long Term Comparison of Double Layer Continuously Locked Closure of Uterine Incision in Cesarean Section Versus Double Layer Purse String Closure (Turan Technique): A Prospective Randomized Study Completed NCT01289262
48 Conservative Stepwise Surgical Approach for Management of Placenta Previa Accreta: a Prospective Case Series Study Completed NCT04981483
49 Plasma Concentration of Biological Markers in Placenta Spectrum Completed NCT04525534
50 Diagnostic Accuracy of Placental Thickness in Lower Uterine Segment Measured By Ultrasound in Prediction of Placenta Accreta Spectrum in Patients With Placenta Previa. A Diagnostic Test Accuracy Study Completed NCT05500404

Search NIH Clinical Center for Placenta Accreta

Cochrane evidence based reviews: placenta accreta

Sources

Genetic Tests for Placenta Accreta

About this section
Sources

Anatomical Context for Placenta Accreta

About this section

Organs/tissues related to Placenta Accreta:

MalaCards : Placenta, Uterus, Myeloid, Liver, Cervix, Whole Blood, Endothelial
Sources

Publications for Placenta Accreta

About this section

Articles related to Placenta Accreta:

(show top 50) (show all 2306)
# Title Authors PMID Year
1
Placental bands on MRI in the setting of placenta accreta spectrum: Case report with radiologic-pathologic correlation. 62
36439927 2023
2
The impact of preoperative ultrasound and intraoperative findings on surgical outcomes in patients at high risk of placenta accreta spectrum. 62
36054504 2023
3
Clinical features at the time of non-hysteroscopic myomectomy before pregnancy, which affect adverse pregnancy outcomes: a retrospective cohort study. 62
36463110 2022
4
Neuraxial to general anesthesia conversion has equitable intraoperative and improved post-operative outcomes compared to general anesthesia in cesarean hysterectomy for placenta accreta spectrum (PAS). 62
34657560 2022
5
Pregnancy outcome in women with prior placenta accreta spectrum disorders treated with conservative-reconstructive surgery: analysis of 202 cases. 62
33843411 2022
6
Complicated placenta accreta spectrum: identifying a high-risk cohort. 62
34112053 2022
7
Management of placenta accreta spectrum disorders in COVID 19 patients. 62
34814799 2022
8
Efficacy of distal haemostasis during caesarean delivery in women with placenta accreta spectrum disorders. 62
34794371 2022
9
Effectiveness of preventive B-Lynch sutures in patients at a high risk of postpartum hemorrhage. 62
36089573 2022
10
Comparison between a prenatal sonographic scoring system and a clinical grading at delivery for Placenta Accreta Spectrum disorders. 62
34818979 2022
11
Prediction of clinical outcomes in women with placenta accreta spectrum using machine learning models: an international multicenter study. 62
34233555 2022
12
Cook Cervical Ripening Balloon for placenta accreta spectrum disorders with placenta previa: a novel approach to uterus preserving. 62
35290491 2022
13
Total vs. supracervical hysterectomy for placenta accreta spectrum disorders. 62
33749489 2022
14
Decreases in resource use after implementing an interdisciplinary management program for patients with placenta accreta spectrum. 62
33356709 2022
15
The use of methotrexate in conservative treatment of placenta accreta spectrum disorders. 62
34278931 2022
16
Maternal Serum Cripto-1 Levels in Pregnancies Complicated with Placenta Previa and Placenta Accreta Spectrum (PAS). 62
36474377 2022
17
Filling the bladder technique at cesarean hysterectomy for placenta accreta spectrum disorders: not solely to avoid bladder injury. 62
33573435 2022
18
The clinical utility of magnetic resonance imaging as an adjunct to ultrasound in the diagnosis of placenta accreta spectrum disorders. 62
33771092 2022
19
Macrophage polarization in placenta accreta and macrophage-trophoblast interactions. 62
36000792 2022
20
Cervicovesical U-suture: An effective novel alternative to partial cystectomy for controlling life-threatening postpartum hemorrhage due to placenta accreta spectrum invading the bladder. 62
35729022 2022
21
Association of the placenta accreta spectrum score and estimated blood loss in placenta accreta spectrum patients with placenta previa: a retrospective cohort study. 62
36173551 2022
22
Risk of unscheduled delivery in women with placenta accreta according to planned gestational age at delivery. 62
33504230 2022
23
Placenta accreta spectrum disorders in twin pregnancies as an under reported clinical entity: a case series and systematic review. 62
35282751 2022
24
REBOA placement for placenta accreta spectrum: patient selection and utilization. 62
33926349 2022
25
Placenta accreta spectrum in vulnerable population: How to provide care for pregnant refugees struggling to access affordable healthcare. 62
33455510 2022
26
Management practices for placenta accreta spectrum patients: a Latin American hospital survey. 62
33843408 2022
27
Management of pregnancies complicated by placenta accreta spectrum utilizing a multidisciplinary care team in a rural state. 62
33769169 2022
28
Placenta accreta spectrum: intraoperatory analysis for immediate tele-help. 62
35057705 2022
29
Neonatal outcome after conservative-reconstructive surgery for placenta accreta spectrum disorders. 62
33441040 2022
30
Whole blood transfusion reduces overall component transfusion in cases of placenta accreta spectrum: a pilot program. 62
33902384 2022
31
Evaluation of the Tramline Sign in the Prediction of Placenta Accreta Spectrum and Perioperative Outcomes in Anterior Placenta Previa. 62
33556967 2022
32
Prediction of placenta accreta spectrum by combining deep learning and radiomics using T2WI: a multicenter study. 62
36094660 2022
33
Aortic balloon occlusion at surgery for placenta accreta spectrum: is the occlusion at the level of the renal artery necessary? 62
34496703 2022
34
Abnormal placenta implantation. Integration between first- and third-trimester imaging in predicting the severity of Placenta Accreta Spectrum (PAS) disorders. 62
36468282 2022
35
Does a more exact definition mean being able to reduce maternal morbidity in placenta accreta spectrum? 62
35841939 2022
36
Diffusion and perfusion MRI parameters in the evaluation of placenta accreta spectrum disorders in patients with placenta previa. 62
35802217 2022
37
Advantages of intraoperative staging and topographic classification in placenta accreta spectrum. 62
35940224 2022
38
Bulking suture-ligation of the arcuate artery for addressing bleeding from placenta accreta spectrum disorders. 62
35788325 2022
39
Short interval pregnancy is associated with pathology severity in placenta accreta spectrum (PAS). 62
34818975 2022
40
Telemedicine as a strategy to facilitate placenta accreta spectrum treatment. 62
34486453 2022
41
Correlation of clinical outcomes with the application of the 2020 consensus panel on histological classification for Placenta Accreta Spectrum (PAS). 62
35703727 2022
42
Ultrasound detection rates of the placenta accreta spectrum with prior myomectomy. 62
34763606 2022
43
Maternal hemodynamics during aortic occlusion with REBOA in patients with placenta accreta spectrum disorder. 62
33618605 2022
44
Surgical advances in the management of placenta accreta spectrum: establishing new expectations for operative blood loss. 62
33272057 2022
45
Emergency embolization of a massive life-threatening placenta percreta bleeding following delivery by Cesarean section. 62
36193271 2022
46
Second-trimester abortion care for those with complex medical conditions. 62
36036465 2022
47
Intraplacental T2-hypointense bands may help predict placental invasion depth and postpartum hemorrhage in placenta accrete spectrum disorders in high-risk gravid patients. 62
36116713 2022
48
Correlation of placental thickness and placenta percreta in patients with placenta previa: findings from MRI. 62
36114883 2022
49
Maternal mortality in women with pre-viable premature rupture of membranes: An analysis from the French confidential enquiry into maternal deaths. 62
36207816 2022
50
Normal placental structural anatomy: ultrasound and doppler features elucidated with US-MR image fusion and ferumoxytol-enhanced MRI. 62
36462034 2022
Sources

Variations for Placenta Accreta

About this section
Sources

Expression for Placenta Accreta

About this section
Search GEO for disease gene expression data for Placenta Accreta.
Sources

Pathways for Placenta Accreta

About this section

Pathways related to Placenta Accreta according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.45 VEGFA TEK SERPINE1 RXFP1 PGF OXT
2
PAK Pathway 64
Show member pathways
 13.24 TEK PGF KDR FLT1 CTNNB1 CDH1
3
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.13 VEGFA TEK PGF KDR FLT1 CTNNB1
4
PI3K-Akt signaling pathway 74
Show member pathways
 12.87 VEGFA TEK PGF KDR FLT1 ANGPT2
5
Signaling by Receptor Tyrosine Kinases 66
12.75 VEGFA PGF KDR FLT1 CTNNB1
6
VEGF Pathway (Qiagen) 64
Show member pathways
 12.35 VEGFA PGF KDR FLT1
7
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.29 TEK PGF KDR FLT1 CTNNB1 CDH1
8
Signaling by VEGF 66
Show member pathways
 12.15 VEGFA PGF KDR FLT1 CTNNB1
9
Focal adhesion 74
12.1 CTNNB1 FLT1 KDR PGF VEGFA
10
Tyrosine Kinases / Adaptors 3
12.05 TEK KDR FLT1 ANGPT2
11
Gastrin signaling pathway 74
11.9 VEGFA SERPINE1 CTNNB1 CDH1
12
Malignant pleural mesothelioma 74
11.84 VEGFA TEK PGF KDR FLT1 CTNNB1
13
Hippo-Merlin signaling dysregulation 74
Show member pathways
 11.77 TEK KDR FLT1 CTNNB1
14
Clear cell renal cell carcinoma pathways 74
11.75 VEGFA KDR FLT1
15
Angiogenesis (CST) 3
11.75 TEK KDR FLT1 ANGPT2
16
Transcription_P53 signaling pathway 22
11.64 CTNNB1 FLT1 KDR VEGFA
17
SHP2 signaling 61
11.53 VEGFA TEK KDR
18
NRP1-triggered signaling pathways in pancreatic cancer 74
11.52 VEGFA KDR FLT1
19
Signaling events mediated by VEGFR1 and VEGFR2 61
11.47 VEGFA KDR FLT1 CTNNB1
20
Genes controlling nephrogenesis 74
11.42 VEGFA KDR CTNNB1
21
Vemurafenib Pathway, Pharmacodynamics 60
11.4 VEGFA KDR FLT1
22
Photodynamic therapy-induced HIF-1 survival signaling 74
11.31 VEGFA SERPINE1 ANGPT2
23
VEGFR1 specific signals 61
11.11 FLT1 PGF VEGFA
24
G-protein signaling_Rap2B regulation pathway 22
10.94 TEK PGF KDR FLT1 CDH1 ANGPT2
25
HIF-2-alpha transcription factor network 61
10.93 VEGFA SERPINE1 KDR FLT1
26
Angiogenesis (WikiPathways) 74
10.91 TEK KDR FLT1
27
S1P3 pathway 61
10.83 VEGFA FLT1
28
S1P1 pathway 61
10.8 VEGFA KDR
29
H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity 74
10.79 CTNNB1 CDH1
30
VEGF ligand-receptor interactions 66
Show member pathways
 10.46 VEGFA PGF KDR FLT1
31
Robo4 and VEGF signaling pathways crosstalk 74
10.41 VEGFA KDR
32
Regorafenib Pathway, Pharmacodynamics 60
10.4 TEK KDR FLT1
33
SARS-CoV-2 altering angiogenesis via NRP1 74
10.3 VEGFA KDR
Sources

GO Terms for Placenta Accreta

About this section

Cellular components related to Placenta Accreta according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.98 VEGFA SERPINE1 PGF PAPPA OXT MIR29A
2 extracellular region GO:0005576 9.68 AFP ANGPT2 CDH1 CGB3 FLT1 INSL4

Biological processes related to Placenta Accreta according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.21 VEGFA MIR34A MIR29A KDR CTNNB1
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.2 BDKRB2 FLT1 KDR TEK
3 positive regulation of MAPK cascade GO:0043410 10.09 VEGFA TEK KDR FLT1 CTNNB1
4 positive regulation of endothelial cell proliferation GO:0001938 10.06 VEGFA TEK PGF KDR
5 negative regulation of endothelial cell apoptotic process GO:2000352 10.02 TEK SERPINE1 KDR
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.02 FLT1 KDR TEK VEGFA
7 sprouting angiogenesis GO:0002040 10.01 VEGFA TEK PGF
8 cellular response to vascular endothelial growth factor stimulus GO:0035924 10 VEGFA KDR FLT1
9 branching involved in blood vessel morphogenesis GO:0001569 9.99 VEGFA KDR CTNNB1
10 positive regulation of focal adhesion assembly GO:0051894 9.97 VEGFA TEK KDR
11 angiogenesis GO:0001525 9.97 VEGFA TEK SERPINE1 PGF KDR FLT1
12 negative regulation of cell migration GO:0030336 9.95 CDH1 MIR29A MIR34A MIR518B SERPINE1
13 vascular wound healing GO:0061042 9.92 VEGFA KDR
14 negative regulation of angiogenesis GO:0016525 9.92 TEK MIR34A MIR29A CTNNB1 ANGPT2
15 positive regulation of mast cell chemotaxis GO:0060754 9.91 VEGFA PGF
16 positive regulation of endothelial cell migration GO:0010595 9.91 VEGFA TEK MIR29A KDR
17 cellular response to indole-3-methanol GO:0071681 9.89 CTNNB1 CDH1
18 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.88 VEGFA KDR
19 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.88 VEGFA KDR
20 Tie signaling pathway GO:0048014 9.87 ANGPT2 TEK
21 glomerulus vasculature development GO:0072012 9.86 ANGPT2 TEK
22 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.86 FLT1 KDR PGF VEGFA
23 negative regulation of vascular wound healing GO:0061044 9.79 SERPINE1 MIR34A
24 vascular endothelial growth factor signaling pathway GO:0038084 9.56 VEGFA PGF KDR FLT1
25 positive regulation of angiogenesis GO:0045766 9.5 VEGFA TEK SERPINE1 PGF MIR29A KDR

Molecular functions related to Placenta Accreta according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 TEK KDR FLT1
2 vascular endothelial growth factor receptor activity GO:0005021 9.26 KDR FLT1
3 vascular endothelial growth factor receptor binding GO:0005172 8.92 VEGFA PGF
Sources

Sources for Placenta Accreta

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....